In National Advertising Division Challenge, Regen Doctors Voluntarily Discontinues Compounded Semaglutide Product Claims
New York, NY – November 20, 2025 – Following a challenge brought by Novo Nordisk Inc., BBB National Programs’ National Advertising Division reviewed express and implied advertising claims made by Regen Doctors, Inc. for its compounded semaglutide products that appeared on Regen’s website.
Regen Doctors is a telehealth company located in Allentown, Pennsylvania that markets compounded drugs to patients and physicians in many U.S. states. Challenger Novo Nordisk is a global pharmaceutical company specializing in diabetes care as well as other chronic conditions including obesity, rare diseases, and cardiovascular conditions. Novo Nordisk markets the only FDA-approved semaglutide medicines, including Rybelsus®, Ozempic® and Wegovy®.
Novo Nordisk challenged Regen Doctors' express and implied claims regarding its compounded semaglutide product’s claimed superiority, safety, efficacy, and health benefits.
During the inquiry, Regen Doctors informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.
Regen Doctors is a telehealth company located in Allentown, Pennsylvania that markets compounded drugs to patients and physicians in many U.S. states. Challenger Novo Nordisk is a global pharmaceutical company specializing in diabetes care as well as other chronic conditions including obesity, rare diseases, and cardiovascular conditions. Novo Nordisk markets the only FDA-approved semaglutide medicines, including Rybelsus®, Ozempic® and Wegovy®.
Novo Nordisk challenged Regen Doctors' express and implied claims regarding its compounded semaglutide product’s claimed superiority, safety, efficacy, and health benefits.
During the inquiry, Regen Doctors informed the National Advertising Division (NAD) that it had permanently discontinued the challenged claims. Therefore, NAD did not review the claims on their merits and will treat the discontinued claims, for compliance purposes, as though NAD recommended they be discontinued.
All BBB National Programs case decision summaries can be found in the case decision library. For the full text of NAD, NARB, and CARU decisions, subscribe to the online archive. Per NAD/NARB Procedures, this release may not be used for promotional purposes.